United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News Why Inhibikase Therapeutics (NASDAQ: IKT) is tapping public markets now for $100m in new funding Find out how Inhibikase Therapeutics plans to use its $100M equity raise to fund pipeline trials and what it means for shareholders in 2025. byVenkateshNovember 21, 2025